How to Measure Disease Activity, Impact, and Control in Patients with Recurrent Wheals, Angioedema, or Both

Gaig, 2004, Epidemiology of urticaria in Spain, J Invest Allergol Clin Immunol, 14, 214 Zuberbier, 2018, The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria, Allergy, 73, 1393, 10.1111/all.13397 Maurer, 2018, The international WAO/EAACI guideline for the management of hereditary angioedema—the 2017 revision and update, Allergy, 73, 1575, 10.1111/all.13384 O’Donnell, 1997, The impact of chronic urticaria on the quality of life, Br J Dermatol, 136, 197, 10.1111/j.1365-2133.1997.tb14895.x Engin, 2008, The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria, J Eur Acad Dermatol Venereol, 22, 36, 10.1111/j.1468-3083.2007.02324.x Ozkan, 2007, Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria, Ann Allergy Asthma Immunol, 99, 29, 10.1016/S1081-1206(10)60617-5 Sullivan, 2011, A primer on the validity of assessment instruments, J Grad Med Educ, 3, 119 Hays, 2000, The concept of clinically meaningful difference in health-related quality of life research, Pharmacoeconomics, 18, 419, 10.2165/00019053-200018050-00001 Lennox, 2004, Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life, Ann Allergy Asthma Clin Immunol, 93, 142, 10.1016/S1081-1206(10)61466-4 Stull, 2017, Analysis of disease activity scores in chronic spontaneous/idiopathic urticaria, Br J Dermatol, 177, 1093, 10.1111/bjd.15454 Zachariae, 2012, Itch severity and quality of life in patients with pruritus: preliminary validity of a Danish adaptation of the itch severity scale, Acta Dermato Venereologica, 92, 508, 10.2340/00015555-1221 Mathias, 2012, Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria, Ann Allergy Asthma Immunol, 108, 20, 10.1016/j.anai.2011.09.008 Erol, 2021, Fatigue is common and predicted by female gender and sleep disturbance in patients with chronic spontaneous urticaria, J Allergy Clin Immunol Pract, 9, 469, 10.1016/j.jaip.2020.08.020 Mann, 2020, Sleep disturbance in patients with urticaria and atopic dermatitis: an underestimated burden, Acta Derm Venereol, 100, adv00073, 10.2340/00015555-3416 He, 2018, Association between sleep disorders and subsequent chronic spontaneous urticaria development: a population-based cohort study, Medicine, 97, e11992, 10.1097/MD.0000000000011992 Yosipovitch, 2008, Chronic idiopathic urticaria: a "Cinderella" disease with a negative impact on quality of life and health care costs, Arch Dermatol, 144, 102, 10.1001/archdermatol.2007.6 Hawro, 2018, Comparison and interpretability of the available urticaria activity scores, Allergy, 73, 251, 10.1111/all.13271 Hawro, 2018, The Urticaria Activity Score—validity, reliability, and responsiveness, J Allergy Clin Immunol Pract, 6, 1185, 10.1016/j.jaip.2017.10.001 Greaves, 1981, Antihistamine treatment: a patient self-assessment method in chronic urticaria, Br Med J (Clin Res Ed), 283, 1435, 10.1136/bmj.283.6304.1435-a Baiardini, 2005, A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL), Allergy, 60, 1073, 10.1111/j.1398-9995.2005.00833.x Baiardini, 2019, Minimal important difference of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL), Allergy, 74, 2542, 10.1111/all.13939 Weller, 2014, Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control, J Allergy Clin Immunol, 133, 1365, 10.1016/j.jaci.2013.12.1076 Ohanyan, 2017, Responsiveness and minimal important difference of the urticaria control test, J Allergy Clin Immunol, 140, 1710, 10.1016/j.jaci.2017.04.050 Weller, 2013, Development, validation, and initial results of the Angioedema Activity Score, Allergy, 68, 1185, 10.1111/all.12209 Aygören-Pürsün, 2016, Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat, J Allergy Clin Immunol, 138, 934, 10.1016/j.jaci.2016.03.043 Staubach, 2018, Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data, Allergy, 73, 576, 10.1111/all.13339 Weller, 2020, Development of the Angioedema Control Test—a patient-reported outcome measure that assesses disease control in patients with recurrent angioedema, Allergy, 75, 1165, 10.1111/all.14144 Weller, 2020, Validation of the Angioedema Control Test (AECT)—a patient-reported outcome instrument for assessing angioedema control, J Allergy Clin Immunol Pract, 8, 2050, 10.1016/j.jaip.2020.02.038 Weller, 2012, Development and construct validation of the Angioedema Quality of Life Questionnaire, Allergy, 67, 1289, 10.1111/all.12007 Weller, 2016, The Angioedema Quality of Life Questionnaire (AE-QoL)—assessment of sensitivity to change and minimal clinically important difference, Allergy, 71, 1203, 10.1111/all.12900 Kulthanan, 2019, Angioedema Quality of Life Questionnaire (AE-QoL)—interpretability and sensitivity to change, Health Qual Life Outcomes, 17, 160, 10.1186/s12955-019-1229-3 Lumry, 2020, Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study, Allergy, 76, 1188, 10.1111/all.14680 Aygören-Pürsün, 2018, Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema, N Engl J Med, 379, 352, 10.1056/NEJMoa1716995 Fukunaga, 2020, Efficacy, pharmacokinetics, pharmacodynamics, and safety of intravenous C1 inhibitor for long-term prophylaxis and treatment of breakthrough attacks in Japanese subjects with Hereditary Angioedema: a Phase 3 open-label study, Arerugi, 69, 192 Riedl, 2018, Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study, Allergy, 73, 1871, 10.1111/all.13466 Weller, 2017, Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase, Allergy Asthma Proc, 38, 143, 10.2500/aap.2017.38.4025 Forjaz, 2021, HAE-AS, a specific disease activity scale for hereditary angioedema with C1-inhibitor deficiency, J Investig Allergol Clin Immunol, 31 Betschel, 2019, The International/Canadian Hereditary Angioedema Guideline, Allergy Asthma Clin Immunol, 15, 72, 10.1186/s13223-019-0376-8 Prior, 2012, Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project, Health Qual Life Outcomes, 10, 82, 10.1186/1477-7525-10-82 Banerji, 2018, Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial, JAMA, 320, 2108, 10.1001/jama.2018.16773 Prior, 2016, Psychometric field study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL, J Allergy Clin Immunol Pract, 4, 464, 10.1016/j.jaip.2015.12.010 Zanichelli, 2018, Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert) in patients with hereditary angioedema: the SABHA study, Orphanet J Rare Dis, 13, 51, 10.1186/s13023-018-0797-3 Bygum, 2017, Disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema, Front Med (Lausanne), 4, 212, 10.3389/fmed.2017.00212 Squeglia, 2016, High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study, Orphanet J Rare Dis, 11, 133, 10.1186/s13023-016-0518-8 Banerji, 2020, Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States, Ann Allergy Asthma Immunol, 124, 600, 10.1016/j.anai.2020.02.018 Busse, 2019, Development of a health-related quality of life instrument for patients with hereditary angioedema living in the United States, J Allergy Clin Immunol Pract, 7, 1679, 10.1016/j.jaip.2018.11.042